mCRPC: Latest developments in diagnostics and combination therapies

Bookmark and Share
Published: 4 Jun 2021
Views: 3667
Rating:
Save
Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor

Dr Eleni Efstathiou (University of Athens, Athens, Greece), Prof Fred Saad (University of Montreal Hospital Center, Montreal, Canada) and Prof Oliver Sartor (Tulane Cancer Center, New Orleans, USA) discuss the latest developments in diagnostics and combination therapies for mCRPC.

Initially, they discuss the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer. They then discuss the ACIS study and what it means for mCRPC patients. Prof Sartor and Dr Efstathiou also talk about circulating tumour DNA fraction to independently predict clinical outcomes in patients with metastatic castration-resistant prostate cancer. Dr Efstathiou mentions the ODENZA study which is then further discussed. In the end, they talk about the future of mCRPC research and other studies of significance regarding it.

 

Results from the VISION Trial
Results from the ACIS trial
The future with regards to treatment of elderly patients
Combination therapies for mCRPC
Bipolar androgen therapy (BAT) and nivolumab for mCRPC patients
Results from ODENZA Trial
ctDNA% to independently predict for clinical outcomes in patients with mCRPC
Take home message from ASCO 2021

This programme has been supported by an unrestricted educational grant from Janssen.